Union européenne -
français -
EMA (European Medicines Agency)
jemperli
glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.
Canada -
français -
Health Canada
jemperli solution
glaxosmithkline inc - dostarlimab - solution - 50mg - dostarlimab 50mg
Suisse -
français -
Swissmedic (Swiss Agency for Therapeutic Products)
jemperli 500 mg/10 ml solution à diluer pour perfusion
glaxosmithkline ag - dostarlimabum - solution à diluer pour perfusion - dostarlimabum 500 mg, natrii citras dihydricus, acidum citricum monohydricum, arginini hydrochloridum, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 22.78 mg. - endometriumkarzinom - biotechnologika